Alluvi, previously BI 4744, offers a notable advance in obesity treatment. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates compelling efficacy in patient https://socialwoot.com/story24124091/alluvi-a-comprehensive-dive-into-retatrutide-s-potential